Clinical Trial Update: Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating adjuvant ipilimumab and nivolumab in high-risk ocular melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Ocular Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Suthee Rapisuwon | Conditions: Melanoma, Ocular Melanoma | Phase 2 | Status: UNKNOWN